Conquering Diseases

Study Of An Investigational Drug Combination For Acute Lymphoblastic Leukemia (All)

Description

Seeking people aged 2-21 years who have been diagnosed with Philadelphia chromosome positive (Ph+) or ABL-class fusion positive Acute Lymphoblastic Leukemia (ALL) for a study of whether using a less toxic chemotherapy in combination with a drug called imatinib can keep the cancer from returning after treatment.

Overview

Participants in this study will receive chemotherapy in combination with imatinib. What type of chemotherapy the participant will receive will be based on a bone marrow or blood test for minimal residual disease.

What we're hoping for

This study will evaluate whether using a less toxic chemotherapy in combination with a drug called imatinib can help prevent Acute Lymphoblastic Leukemia (ALL) from coming back after treatment.

Additional Information

ClinicalTrials.gov Identifier: NCT03007147

 Principal Investigator

Stefanie  Lowas, MD

University of Massachusetts Medical School

 Study Contact

Danielle  Pichette-Patsky

+1 508-856-3077

Danielle.Pichette-Patsky@umassmed.edu

 Location

UMMS University Campus

55 Lake Ave North 

Worcester,MA 01655

508-856-8989